GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

finotonlimab   Click here for help

GtoPdb Ligand ID: 14401

Synonyms: An Youping® (China) | SCT-I10A
Approved drug Immunopharmacology Ligand
finotonlimab is an approved drug
Compound class: Antibody
Comment: Finotonlimab (SCT-I10A) is a humanized IgG4 monoclonal antibody that targets programmed cell death 1 receptor (PD-1) for anti-tumour potential [3].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Finotonlimab (SCT-I10A) was progressed as a clinical lead for advanced solid tumours. First approval was granted by China's NMPA in 2025, to treat recurrent and/or metastatic squamous cell carcinoma of the head and neck (in combination with platinum-containing chemotherapy) [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04560894 SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma Phase 2/Phase 3 Interventional Sinocelltech Ltd.
NCT04146402 SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma Phase 3 Interventional Sinocelltech Ltd. 2